Effect of drospirenone/ethinylestradiol(Ⅱ) on serum anti-Müllerian hormone level in Chinese polycystic ovary syndrome women

doi:10.3969/j.issn.1006-7795.2021.04.007

Abstract

Abstract: Objective To evaluate the effect of drospirenone/ethinylestradiol(Ⅱ)(pills for contraception and use for the treatment of hyperandrogenenism) on serum anti-Müllerian hormone(AMH) level in Chinese polycystic ovary syndrome (PCOS) patients. Methods Totally 74 PCOS patients who were admitted to the Department of Gynecological Endocrinology,Beijing Obstetrics and Gynecology Hospital,Capital Medical University,China from August 2020 to April 2021 were enrolled in this study. The serum AMH,sex hormones,liver and kidney function were measured before and after the use of drospirenone/ethinylestradiol tablets (Ⅱ). The patients were divided into three groups according to the duration of taking pills: group A(n=16) for 3 cycles,group B (n=28) for 4-6 cycles and group C(n=30) for more than 6 cycles. Results The median serum AMH level after treatment (5.80 ng/mL) was significant lower than that before treatment (9.17 ng/mL) (P＜0.001). The median change of AMH level before and after the use of drospirenone/ethinylestradiol tablets(Ⅱ) was 2.53 ng/mL. The median serum AMH were 9.01 ng/mL,7.79 ng/mL and 10.19 ng/mL before treatment and 7.01 ng/mL,5.06 ng/mL and 6.70 ng/mL after treatment in group A,group B and group C,respectively. The serum AMH was decreased after treatment in all groups. Conclusion Taking drospirenone and ethinylestradiol II for 3 cycles or more could reduce the serum AMH level in PCOS patients.

Key words: polycystic ovary syndrome, anti-Müllerian hormone, drospirenone/ethinylestradiol(Ⅱ)

CLC Number:

R711.75

Yang Yu, Ruan Xiangyan, Ju Rui, Xu Xin, Gu Muqing, Cheng Jiaojiao. Effect of drospirenone/ethinylestradiol(Ⅱ) on serum anti-Müllerian hormone level in Chinese polycystic ovary syndrome women[J]. Journal of Capital Medical University, 2021, 42(4): 547-552.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2021.04.007

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2021/V42/I4/547

References

[1] Lizneva D,Suturina L,Walker W,et al. Criteria,prevalence,and phenotypes of polycystic ovary syndrome[J]. Fertil Steril,2016,106(1):6-15.
[2] 中华医学会妇产科学分会内分泌学组及指南专家组.多囊卵巢综合征中国诊疗指南[J]. 中华妇产科杂志,2018,53(1):2-6.
[3] di Clemente N,Racine C,Pierre A,et al. Anti-Mullerian hormone in female reproduction[J]. Endocr Rev,2021, Epub ahead of print.
[4] 王虎生,阮祥燕,李雪,等. 抗苗勒管激素与抑制素B对多囊卵巢综合征的临床预测价值[J]. 首都医科大学学报,2017,38(4):492-497.
[5] Hsu J Y,James K E,Bormann C L,et al. Müllerian-inhibiting substance/anti-müllerian hormone as a predictor of preterm birth in polycystic ovary syndrome[J]. J Clin Endocrinol Metab,2018,103(11):4187-4196.
[6] Hu K,Liu F,Xu H,et al. High antimüllerian hormone levels are associated with preterm delivery in patients with polycystic ovary syndrome[J]. Fertil Steril,2020,113(2):444-452.
[7] The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J]. Fertil Steril,2004,81(1):19-25.
[8] Lie F S,Visser J A,Welt C K,et al. Serum anti-Müllerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood[J]. J Clin Endocrinol Metab,2012,97(12):4650-4655.
[9] Orisaka M,Miyazaki Y,Shirafuji A,et al. The role of pituitary gonadotropins and intraovarian regulators in follicle development: A mini-review[J]. Reprod Med Biol,2021,20(2):169-175.
[10] 邱玲,李丹丹,程歆琦. 抗缪勒管激素的临床应用[J]. 协和医学杂志,2017,8(Z2):229-234.
[11] 袁莹莹,宋晓霞,赵君利,等. 不同年龄组PCOS患者AMH水平及助孕结局分析[J]. 宁夏医科大学学报,2021,43(3):239-243.
[12] 万德花,程强军. 不同年龄段PCOS患者血液AMH水平的临床研究[J]. 生殖医学杂志,2018,27(8):787-789.
[13] Amer S A K S,James C,Al-Hussaini T K,et al. Assessment of circulating anti-müllerian hormone in women using hormonal contraception: a systematic review[J]. J Women's Health,2020,29(1):100-110.
[14] 宋颖,李蓉. 多囊卵巢综合征中国诊疗指南解读[J]. 实用妇产科杂志,2018,34(10):737-741.
[15] 杨荔凡,张艳. 屈螺酮炔雌醇复合片对多囊卵巢综合征患者的有效性探讨[J]. 中外女性健康研究,2019(23):85-101.
[16] Li Y,Ruan X,Wang H,et al. Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment[J]. Fertil Steril,2018,109(4):720-727.
[17] Christ J P,Gunning M N,Meun C,et al. Pre-conception characteristics predict obstetrical and neonatal outcomes in women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab,2019,104(3):809-818.